Global Community

Over the last year, the share price of Procter & Gamble (PG:NYSE) has fallen from around $175 to roughly $140, with most of the decline occurring since March. This weakness may partly reflect layoffs announced earlier in the year amid tariff-related uncertainty, and the stock may now be drifting into oversold territory.Read more

AnyColor Inc’s FY 2025 provided solid evidence that refocusing their business structure and resources would provide the necessary catalyst to achieve self sufficiency in a market largely plagued by lack of imagination and stagnation. Realizing their lack of understanding in an English market and audience, a refocus on the Japanese and Asian markets have produced significant results, cut costs and as a result shareholders have rewarded Nijisanji’s efforts with strong market backing which propelled their share price past all-time highs.Read more

In a nut shell, I saw Butterfly Network as a medical break through and bought a few hundred shares at a $1.55/shr. and the following news confirmed my reasoning of buying; On November 17, 2025, Butterfly Network’s subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology, securing a US$15 million upfront payment, US$10 million annual license fees, and further milestone and revenue-sharing potential.Read more

When I look at an investment, I look for more than just numbers—I look for a story of impact, scalability, and sustainability. Optasia is that story.Read more

Revenue Growth : GE Vernova is expected to grow its revenue by 13% , contributing to a total revenue of US$77 billion. Earnings Forecast : Estimated earnings for 2030 are US$4.2 billion , translating into a market capitalization of US$270.06 billion , based on a 64.68x price-to-earnings ratio.Read more

I like the prospects of all the optical build out in AI data centers. The only supplier of glass for apple iPhone.Read more

Assumptions Where do you think revenue will be in 5 years time? and why?Read more

The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more

Using the Buffett Value Calculation with P/E = $46.02, Growth Rate = 39.18%, and EPS ttm = $0.55 (source: FinViz, 12/8/25) - the Estimated Share Price is $79.54 with a Buy Price set at $39.77 or less.Read more